MedPath

Cetirizine

Generic Name
Cetirizine
Brand Names
Aller-tec, Aller-tec D, Quzyttir, Reactine, Wal Zyr 24 Hour Allergy, Wal Zyr D, Wal-zyr, Zerviate, Zyrtec, Zyrtec-D
Drug Type
Small Molecule
Chemical Formula
C21H25ClN2O3
CAS Number
83881-51-0
Unique Ingredient Identifier
YO7261ME24

Overview

Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called allergic rhinitis. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals . Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects . Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects .

Background

Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called allergic rhinitis. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals . Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects . Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor without sedating effects .

Indication

Seasonal Allergic Rhinitis: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes . Perennial allergic rhinitis: This drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing . Chronic urticaria: Cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It markedly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus .

Associated Conditions

  • Allergy to Tree Pollen
  • Chronic Idiopathic Urticaria
  • Flu caused by Influenza
  • Perennial Allergic Rhinitis (PAR)
  • Respiratory Allergy
  • Seasonal Allergic Rhinitis

FDA Approved Products

cetirizine hydrochloride
Manufacturer:Caraco Pharmaceutical Laboratories, Ltd.
Route:ORAL
Strength:1 mg in 1 mL
Approved: 2009/11/11
NDC:57664-181
Cetirizine Hydrochloride
Manufacturer:Preferred Pharmaceuticals Inc.
Route:ORAL
Strength:1 mg in 1 mL
Approved: 2024/03/22
NDC:68788-8282
ZERVIATE
Manufacturer:Harrow Eye, LLC
Route:OPHTHALMIC
Strength:2.4 mg in 1 mL
Approved: 2025/04/23
NDC:82667-015
Childrens 24 Hour Allergy
Manufacturer:Meijer Distribution Inc
Route:ORAL
Strength:5 mg in 5 mL
Approved: 2025/04/29
NDC:41250-475
Cetirizine Hydrochloride (Allergy)
Manufacturer:INNOVUS PHARMACEUTICALS, INC.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2025/04/28
NDC:57483-190

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath